ADARx Pharmaceuticals Announces Clinical Data Presentation at the American Society of Nephrology (ASN) Kidney Week 2025
SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) — ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX-038, an investigational small interfering RNA (siRNA) therapeutic candidate being evaluated for the treatment of complement factor mediated diseases. The poster presentation […]